Zimmer Biomet delivered mixed Q3 results with a 3.7% constant currency revenue growth to $2.06 billion, even as GAAP diluted EPS slipped 13.8% to $1.00 per share.
Zimmer Biomet reported third quarter net sales of $2.063 billion, up 3.1% reported and 3.7% constant currency, while adjusted diluted EPS was $1.90, consistent with the prior year. However, diluted EPS fell 13.8% to $1.00, leaving the quarter mixed rather than a clear beat or miss.
Net sales were $2.063 billion, up 3.1% on a reported basis and 3.7% on a constant currency basis.
Diluted EPS was $1.00, down 13.8%, while adjusted diluted EPS was $1.90, consistent with the prior year period.
Zimmer Biomet posted third-quarter net sales of $2.063 billion, marking a 3.1% increase on a reported basis. While adjusted diluted earnings per share remained flat at $1.90, the company reported a 13.8% decline in GAAP diluted earnings per share to $1.00.
Net sales were $2.063 billion, up 3.1% on a reported basis and 3.7% on a constant currency basis.
Diluted EPS was $1.00, down 13.8%, while adjusted diluted EPS was $1.90, consistent with the prior year period.